Scout Bio
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Scout Bio was a Philadelphia biotechnology company founded in 2016 as a University of Pennsylvania spinout, co-founded by gene therapy pioneer James Wilson of Penn's Gene Therapy Program. It harnessed the genetic revolution transforming human medicine to deliver the future of veterinary medicine: one-time AAV-based gene therapies for major chronic pet conditions — chronic kidney disease, chronic pain and atopic dermatitis — delivered via a single intramuscular injection that induced long-term expression of therapeutic proteins. Scout raised over $60 million, including a $9.3 million round led by Frazier Healthcare Partners, a $20 million Series B co-led by Digitalis Ventures' Companion Fund and RiverVest Venture Partners, and a $33 million Series B2 led by OrbiMed.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Scout Bio is founded in Philadelphia as a University of Pennsylvania spinout, co-founded by James Wilson.
- Series B financing
Scout raises a $20 million Series B co-led by Digitalis Ventures' Companion Fund and RiverVest Venture Partners to advance its one-time pet therapeutics pipeline.
- Series B2 financing
Scout closes a $33 million Series B2 financing to advance its single-injection gene therapy portfolio.
- Acquired by Ceva
Scout Bio is acquired by French animal health leader Ceva Santé Animale, giving Ceva access to a pet gene-therapy pipeline.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.